Maximus Berger

Evidence that complement and coagulation proteins are mediating the clinical response to omega-3 fatty acids: A mass spectrometry-based investigation in subjects at clinical high-risk for psychosis

Subash Raj Susai, Colm Healy, David Mongan, Meike Heurich, Jonah F Byrne, Mary Cannon, Gerard Cagney, Kieran Wynne, Connie Markulev, Miriam R Schafer, Maximus Berger, Nilufar Mossaheb, Monika Schlogelhofer, Stefan Smesny, Ian B Hickie, Gregor E Berger, Eric YH Chen, Lieuwe de Haan, Dorien H Nieman, Merete Nordentoft, et al.

Journal article  |  2022  |  TRANSLATIONAL PSYCHIATRY

Preliminary evidence indicates beneficial effects of omega-3 polyunsaturated fatty acids (PUFAs) in early psychosis. The present s..

Effects of omega-3 polyunsaturated fatty acid supplementation on cognitive functioning in youth at ultra-high risk for psychosis: secondary analysis of the NEURAPRO randomised controlled trial

Nicholas Cheng, Alison McLaverty, Barnaby Nelson, Connie Markulev, Miriam R Schafer, Maximus Berger, Nilufar Mossaheb, Monika Schlogelhofer, Stefan Smesny, Ian B Hicikie, Gregor E Berger, Eric YH Chen, Lieuwe de Haan, Dorien H Nieman, Merete Nordentoft, Anita Riecher-Rossler, Swapna Verma, Rebekah Street, Andrew Thompson, Hok Pan Yuen, et al.

Journal article  |  2022  |  BJPSYCH OPEN

BACKGROUND: Cognitive impairments are well-established features of psychotic disorders and are present when individuals are at ult..

Acceptability and feasibility of a multidomain harmonized data collection protocol in youth mental health

Sarah Youn, Somayra Mamsa, Kelly Allott, Maximus Berger, Andrea Polari, Simon Rice, Lianne Schmaal, Stephen Wood, Suzie Lavoie

Journal article  |  2022  |  EARLY INTERVENTION IN PSYCHIATRY

Objective: To develop targeted treatment for young people experiencing mental illness, a better understanding of the biological, p..

Cannabidiol for Treatment-Resistant Anxiety Disorders in Young People: An Open-Label Trial.

Maximus Berger, Emily Li, Simon Rice, Christopher G Davey, Aswin Ratheesh, Sophie Adams, Henry Jackson, Sarah Hetrick, Alexandra Parker, Tim Spelman, Richard Kevin, Iain S McGregor, Patrick McGorry, G Paul Amminger

Journal article  |  2022  |  J Clin Psychiatry

Background: Treatment resistance is a significant problem among young people experiencing moderate-to-severe anxiety, affecting ne..

Medicinal cannabis for the treatment of anxiety disorders.

Maximus Berger, G Paul Amminger, Iain S McGregor

Journal article  |  2022  |  Aust J Gen Pract

BACKGROUND: Anxiety is second most common reason for medicinal cannabis prescription in Australia and is being treated with both Δ..

Machine learning based prediction and the influence of complement - Coagulation pathway proteins on clinical outcome: Results from the NEURAPRO trial

Subash Raj Susai, David Mongan, Colm Healy, Mary Cannon, Gerard Cagney, Kieran Wynne, Jonah F Byrne, Connie Markulev, Miriam R Schafer, Maximus Berger, Nilufar Mossaheb, Monika Schlogelhofer, Stefan Smesny, Ian B Hickie, Gregor E Berger, Eric YH Chen, Lieuwe de Haan, Dorien H Nieman, Merete Nordentoft, Anita Riecher-Rossler, et al.

Journal article  |  2022  |  BRAIN BEHAVIOR AND IMMUNITY

BACKGROUND: Functional outcomes are important measures in the overall clinical course of psychosis and individuals at clinical hig..

The association of plasma inflammatory markers with omega-3 fatty acids and their mediating role in psychotic symptoms and functioning: An analysis of the NEURAPRO clinical trial

Subash Raj Susai, David Mongan, Colm Healy, Mary Cannon, Barnaby Nelson, Connie Markulev, Miriam R Schafer, Maximus Berger, Nilufar Mossaheb, Monika Schloegelhofer, Stefan Smesny, Ian B Hickie, Gregor E Berger, Eric YH Chen, Lieuwe de Haan, Dorien H Nieman, Merete Nordentoft, Anita Riecher-Roessler, Swapna Verma, Andrew Thompson, et al.

Journal article  |  2021  |  BRAIN BEHAVIOR AND IMMUNITY

There is increasing evidence that dysregulation of polyunsaturated fatty acids (FAs) mediated membrane function plays a role in th..

Citalopram and Cannabidiol In Vitro and In Vivo Evidence of Pharmacokinetic Interactions Relevant to the Treatment of Anxiety Disorders in Young People

Lyndsey L Anderson, Peter T Doohan, Lachlan Oldfield, Richard C Kevin, Jonathon C Arnold, Maximus Berger, G Paul Amminger, Iain S McGregor

Journal article  |  2021  |  JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

BACKGROUND: Cannabidiol (CBD), a major nonintoxicating constituent of cannabis, exhibits anxiolytic properties in preclinical and ..

Toxoplasma gondii, Herpesviridae and long-term risk of transition to first-episode psychosis in an ultra high-risk sample

E Burkhardt, M Berger, RH Yolken, A Lin, HP Yuen, SJ Wood, SM Francey, A Thompson, PD McGorry, B Nelson, AR Yung, GP Amminger

Journal article  |  2021  |  SCHIZOPHRENIA RESEARCH

BACKGROUND: Ultra high-risk (UHR) criteria were introduced to identify people at imminent risk of developing psychosis. To improve..

Cannabidiol for at risk for psychosis youth: A randomized controlled trial

G Paul Amminger, Ashleigh Lin, Melissa Kerr, Amber Weller, Jessica Spark, Charlotte Pugh, Sally O'Callaghan, Maximus Berger, Scott R Clark, James G Scott, Andrea Baker, Iain McGregor, David Cotter, Zoltan Sarnyai, Andrew Thompson, Alison R Yung, Brian O'Donoghue, Eoin Killackey, Cathy Mihalopoulos, Hok Pan Yuen, et al.

Journal article  |  2021  |  EARLY INTERVENTION IN PSYCHIATRY

BACKGROUND: No biological treatment has been firmly established for the at-risk stage of psychotic disorder. In this study we aim ..